fluorouracil
fluorouracil 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pancreatic Cancer、Metastatic Pancreatic Cancer、Metastatic Pancreatic Adenocarcinoma、Solid Tumor。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
13 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Astellas Pharma Global Development, Inc.
- Eleison Pharmaceuticals LLC.
- Astellas Pharma Inc
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Merck Sharp & Dohme LLC
- UNC Lineberger Comprehensive Cancer Center
- Fudan University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Brazil、Chile、Czechia、法国、德国、意大利、日本、挪威、Singapore、South Korea
正在招募患者的 fluorouracil 研究
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
II 期招募中中国NCT07165847Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06780111Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
II 期招募中中国NCT06121700Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
II 期招募中中国NCT07806292Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
II 期招募中中国NCT06928584Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
III 期招募中意大利NCT06509126Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
II 期招募中中国NCT07391618PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
II 期招募中美国NCT06245889The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
IV 期招募中中国NCT06368063AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
II 期招募中中国NCT06196697Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
III 期招募中法国NCT04747054Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
II 期招募中中国NCT05671822Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
III 期招募中South KoreaNCT04787354AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
II 期招募中中国NCT06494995Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
II 期招募中中国NCT06988956AB122 Platform Study
I 期招募中日本NCT04999761sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
II 期招募中中国NCT06840665Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
II 期招募中法国NCT05973864Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
III 期招募中中国NCT07595276DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
III 期招募中荷兰NCT06275958The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
IV 期招募中中国NCT06217185Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
I 期 / II 期招募中美国NCT07456852
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。